$0.63
-0.04 (-6.46%)
Open$0.67
Previous Close$0.67
Day High$0.67
Day Low$0.62
52W High$5.31
52W Low$0.52
Volume—
Avg Volume16.23M
Market Cap4.44M
P/E Ratio—
EPS$-2.06
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,920.5% upside
Current
$0.63
$0.63
Target
$25.14
$25.14
$18.28
$25.14 avg
$30.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 204.9K | 501.7K | 427.8K |
| Net Income | -245,012,378 | -539,806,952 | 33.9K |
| Profit Margin | -119,566.5% | -113,588.2% | 7.9% |
| EBITDA | -244,197,285 | -567,900,662 | 68.2K |
| Free Cash Flow | — | — | 23.2K |
| Rev Growth | -59.2% | -59.2% | +6.7% |
| Debt/Equity | 0.00 | 0.00 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |